18. CRISPR Treatment for Beta Thalassemia Gets FDA Green Light

The FDA approved a groundbreaking CRISPR treatment for beta thalassemia, marking another victory for genetic medicine. This therapy edits patients’ blood stem cells to boost hemoglobin production, reducing or eliminating the need for regular blood transfusions. Clinical trials showed remarkable success rates, with most patients becoming transfusion-independent after treatment. The approval process included extensive safety monitoring and long-term follow-up studies. This treatment joins the growing list of approved gene therapies and shows how CRISPR technology moves from lab breakthrough to practical medical treatment.